Charles River Laboratories Intl. Inc vs Redwire Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $298.8 (market cap $14.23B), while Redwire Corporation trades at $9.51 (market cap $2.44B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.8× Redwire Corporation's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Redwire Corporation for 18 Days on average.
| CRL | RDW | |
|---|---|---|
Market Cap | $14.23B | $2.44B |
Volume | 1,176,885 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $310.77 | $25.90 |
52-Week Low | $149.93 | $5.06 |
Typical Hold Time | 33 Days | 18 Days |
Enterprise Value | $17.06B | $1.97B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Redwire Corporation (RDW) trades at $9.53, down 6.93% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, while revenue grew to $335.38M in 2025. Recent positive developments include a $981M Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data centers.
Despite strong analyst support (80% buy ratings) and a $14.88 price target representing 56% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents a high-risk opportunity for investors betting on space infrastructure growth, but requires careful monitoring of profitability improvements and execution on contract wins.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →